AU2017341769B2 - N-Acylethanolamide derivatives and uses thereof - Google Patents

N-Acylethanolamide derivatives and uses thereof Download PDF

Info

Publication number
AU2017341769B2
AU2017341769B2 AU2017341769A AU2017341769A AU2017341769B2 AU 2017341769 B2 AU2017341769 B2 AU 2017341769B2 AU 2017341769 A AU2017341769 A AU 2017341769A AU 2017341769 A AU2017341769 A AU 2017341769A AU 2017341769 B2 AU2017341769 B2 AU 2017341769B2
Authority
AU
Australia
Prior art keywords
pea
rat
acid
compound
acylethanolamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017341769A
Other languages
English (en)
Other versions
AU2017341769A1 (en
Inventor
Andrew D. Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carnot LLC
Original Assignee
Carnot LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carnot LLC filed Critical Carnot LLC
Publication of AU2017341769A1 publication Critical patent/AU2017341769A1/en
Application granted granted Critical
Publication of AU2017341769B2 publication Critical patent/AU2017341769B2/en
Priority to AU2021273632A priority Critical patent/AU2021273632A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
AU2017341769A 2016-10-13 2017-10-12 N-Acylethanolamide derivatives and uses thereof Ceased AU2017341769B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021273632A AU2021273632A1 (en) 2016-10-13 2021-11-26 N-acylethanolamide derivatives and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407796P 2016-10-13 2016-10-13
US62/407,796 2016-10-13
US201762517344P 2017-06-09 2017-06-09
US62/517,344 2017-06-09
PCT/US2017/056353 WO2018071679A1 (en) 2016-10-13 2017-10-12 N-acylethanolamide derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021273632A Division AU2021273632A1 (en) 2016-10-13 2021-11-26 N-acylethanolamide derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2017341769A1 AU2017341769A1 (en) 2019-05-02
AU2017341769B2 true AU2017341769B2 (en) 2021-11-11

Family

ID=61906457

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017341769A Ceased AU2017341769B2 (en) 2016-10-13 2017-10-12 N-Acylethanolamide derivatives and uses thereof
AU2021273632A Abandoned AU2021273632A1 (en) 2016-10-13 2021-11-26 N-acylethanolamide derivatives and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021273632A Abandoned AU2021273632A1 (en) 2016-10-13 2021-11-26 N-acylethanolamide derivatives and uses thereof

Country Status (7)

Country Link
US (2) US10933037B2 (enExample)
EP (1) EP3526215A4 (enExample)
JP (1) JP7041673B2 (enExample)
CN (1) CN110023308A (enExample)
AU (2) AU2017341769B2 (enExample)
CA (1) CA3040258A1 (enExample)
WO (1) WO2018071679A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017341769B2 (en) * 2016-10-13 2021-11-11 Carnot, Llc N-Acylethanolamide derivatives and uses thereof
WO2019213333A1 (en) * 2018-05-04 2019-11-07 Carnot2, Llc Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties
WO2019213335A1 (en) * 2018-05-04 2019-11-07 Carnot2, Llc Orally bioavailable prodrugs of edaravone with altered pharmacokinetic properties and methods of use thereof
US20220162239A1 (en) * 2019-02-21 2022-05-26 Université Claude Bernard Lyon 1 Structured molecular vectors for anti-inflammatory compounds and uses thereof
GB202103884D0 (en) 2021-03-19 2021-05-05 Eliem Therapeutics Uk Ltd Novel process
CN113304683B (zh) * 2021-06-17 2022-12-13 江南大学 葡糖酰胺封端聚醚型表面活性剂、其制备方法及应用
WO2025185743A1 (en) * 2024-03-07 2025-09-12 Centre for Chinese Herbal Medicine Drug Development Limited N-oleoylethanolamide and eubacterium rectale for use in treating diarrhea-predominant irritable bowel syndrome

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2440361A (en) * 1947-08-12 1948-04-27 Lilly Co Eli Process and culture media for the production of penicillin
US5925678A (en) * 1994-03-21 1999-07-20 Lifegroup S.P.A. Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament for practicing neuroprotective action in neuropathological states connected with excitotoxicity
US5990170A (en) * 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
US7090903B2 (en) * 2002-10-07 2006-08-15 Konica Corporation Ink-jet recording sheet
US20150157733A1 (en) * 2012-12-13 2015-06-11 Epitech Group S.R.L. Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127471A1 (de) * 1991-08-20 1993-02-25 Henkel Kgaa Verwendung von aminoalkanolamidestern als verarbeitungshilfsmittel fuer thermoplastische kunststoffe
JP4015710B2 (ja) * 1995-05-31 2007-11-28 生化学工業株式会社 新規擬似糖脂質
NZ336538A (en) * 1996-10-15 2001-11-30 Liposome Co Inc N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
ID29246A (id) 1999-03-11 2001-08-16 Ardenia Investments Ltd Senyawa-senyawa baru untuk pengobatan kanker
ATE243701T1 (de) 1999-03-16 2003-07-15 Ardenia Investments Ltd Polyungesättigte fettsäurederivate und deren verwendung in der krebsbehandlung
JP2004268437A (ja) 2003-03-10 2004-09-30 Konica Minolta Holdings Inc インクジェット記録用紙
FR2925491B1 (fr) 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
EP3003331A4 (en) 2013-06-07 2017-02-22 Loma Linda University Dietary omega-3 fatty acid derived glycerophospholipids to treat neuropathic pain
AU2017341769B2 (en) 2016-10-13 2021-11-11 Carnot, Llc N-Acylethanolamide derivatives and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2440361A (en) * 1947-08-12 1948-04-27 Lilly Co Eli Process and culture media for the production of penicillin
US5925678A (en) * 1994-03-21 1999-07-20 Lifegroup S.P.A. Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament for practicing neuroprotective action in neuropathological states connected with excitotoxicity
US5990170A (en) * 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
US7090903B2 (en) * 2002-10-07 2006-08-15 Konica Corporation Ink-jet recording sheet
US20150157733A1 (en) * 2012-12-13 2015-06-11 Epitech Group S.R.L. Polyethylene glycol derivatives of palmitoylethanolamide and analogous acylethanolamides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRICK GIZZI ET AL, "Molecular Tailored Histidine-Based Complexing Surfactants: From Micelles to Hydrogels", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, (2009-08-01), vol. 2009, no. 23, pages 3953 - 3963 *
Pubchem, (2008-06-09), Database accession no. 24808239, URL: Pubchem Compound *

Also Published As

Publication number Publication date
US11547681B2 (en) 2023-01-10
US20190262288A1 (en) 2019-08-29
JP2019532069A (ja) 2019-11-07
US10933037B2 (en) 2021-03-02
CA3040258A1 (en) 2018-04-19
EP3526215A1 (en) 2019-08-21
CN110023308A (zh) 2019-07-16
AU2021273632A1 (en) 2021-12-16
EP3526215A4 (en) 2020-05-27
JP7041673B2 (ja) 2022-03-24
WO2018071679A1 (en) 2018-04-19
US20210093589A1 (en) 2021-04-01
AU2017341769A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
AU2017341769B2 (en) N-Acylethanolamide derivatives and uses thereof
US11185538B2 (en) Compositions for treating glaucoma or reducing intraocular pressure
US20200352894A1 (en) Combination therapy
US12486226B2 (en) Cannabinoid derivatives
CN104244948A (zh) 在炎症性疾病的治疗中使用的用于调节n-酰基乙醇胺的特异性酰胺酶的组合物和方法
WO2019001383A1 (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
EP2382206B1 (en) Compounds and methods for the treatment of pain and other diseases
WO2019213335A1 (en) Orally bioavailable prodrugs of edaravone with altered pharmacokinetic properties and methods of use thereof
WO2019213333A1 (en) Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties
CA2799893C (en) Novel derivatives of mesalazine, process for their preparation and their use in the treatment of intestinal inflammatory diseases
CA3031815A1 (en) Dermatological formulations of 2-(2-ethoxy-2-oxoethyl)(methyl)amino-2-oxoethyl 5-(tetradecyloxy)furan-2-carboxylate
IT202000007150A1 (it) Inibitori di monoacilglicerolo lipasi (magl)
ES2222822A1 (es) Diamidas de aminoacidos en posicion no alfa utiles como adyuvanes para la administracion de agentes biologicos activos.
JP2022545047A (ja) ３－ヒドロキシ－５－プレグナン－２０－オン誘導体およびその使用
CN103037842B (zh) 药物化合物
AU2021235760A1 (en) Treatment of disorders associated with oxidative stress and compounds for same
CN108794358A (zh) 取代苯磺酰基类化合物及其制备药物的用途
TW201620515A (zh) 作爲組織蛋白去乙醯酶抑制劑的單一鏡相異構物及其製備方法
JPWO2005005390A1 (ja) 新規酵素阻害剤
JPH06157467A (ja) ３−アザビシクロ［３．２．１］オクタン誘導体およびその用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired